Abstract

POSB351 A Prospective Observational Study to Determine the Safety, Efficacy, and Toxicity Profile of Paclitaxel in Patients Receiving Weekly and Three Weekly Doses

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Efficacy and safety of serplulimab (an anti-PD-1 antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy (074)
Jusheng An ... Jun Zhu
Gynecologic oncology | VOL. 166
Jusheng An, et. al.Jusheng An ... Jun Zhu
01 Aug 2022
Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: A single-arm, open-label, phase 2 study.
Lingying Wu ... Kui Jiang
Journal of Clinical Oncology | VOL. 39
Lingying Wu, et. al.Lingying Wu ... Kui Jiang
20 May 2021
180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer
Y Yue ... C Lu
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. 30
Y Yue, et. al.Y Yue ... C Lu
01 Nov 2020
Efficacy of weekly paclitaxel in patients with advanced gastric cancer with prior docetaxel-containing chemotherapy.
Takayuki Ando ... Takashi Kobayashi
Journal of Clinical Oncology | VOL. 30
Takayuki Ando, et. al.Takayuki Ando ... Takashi Kobayashi
01 Feb 2012
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers